103 related articles for article (PubMed ID: 22865459)
21. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids.
Herrmann R; Fayad W; Schwarz S; Berndtsson M; Linder S
J Biomol Screen; 2008 Jan; 13(1):1-8. PubMed ID: 18040052
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis assays for quantifying the bioactivity of anticancer drug products.
Brunelle JK; Zhang B
Drug Resist Updat; 2010 Dec; 13(6):172-9. PubMed ID: 20947411
[TBL] [Abstract][Full Text] [Related]
23. A sensitive assay for the evaluation of cytotoxicity and its pharmacologic modulation in human solid tumor-derived cell lines exposed to cancer-therapeutic agents.
Mirzayans R; Andrais B; Scott A; Tessier A; Murray D
J Pharm Pharm Sci; 2007; 10(2):298s-311s. PubMed ID: 17718933
[TBL] [Abstract][Full Text] [Related]
24. Cancer stem cells as the relevant biomass for drug discovery.
Winquist RJ; Furey BF; Boucher DM
Curr Opin Pharmacol; 2010 Aug; 10(4):385-90. PubMed ID: 20630801
[TBL] [Abstract][Full Text] [Related]
25. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
26. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
Lösler S; Schlief S; Kneifel C; Thiel E; Schrezenmeier H; Rojewski MT
Ann Hematol; 2009 Nov; 88(11):1047-58. PubMed ID: 19301004
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells.
Bosanquet AG; Bell PB
J Exp Ther Oncol; 2004 Jul; 4(2):145-54. PubMed ID: 15500009
[TBL] [Abstract][Full Text] [Related]
28. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
29. The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells?
Ablain J; Nasr R; Bazarbachi A; de Thé H
Cancer Discov; 2011 Jul; 1(2):117-27. PubMed ID: 22586354
[TBL] [Abstract][Full Text] [Related]
30. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
31. Pathophysiologically relevant in vitro tumor models for drug screening.
Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
[TBL] [Abstract][Full Text] [Related]
32. The contemporary drug development process: advances and challenges in preclinical and clinical development.
Garrett MD; Walton MI; McDonald E; Judson I; Workman P
Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
[TBL] [Abstract][Full Text] [Related]
33. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.
Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW
J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653
[TBL] [Abstract][Full Text] [Related]
34. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
Griffiths M; Sundaram H
Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis.
Lau CB; Ho CY; Kim CF; Leung KN; Fung KP; Tse TF; Chan HH; Chow MS
Life Sci; 2004 Jul; 75(7):797-808. PubMed ID: 15183073
[TBL] [Abstract][Full Text] [Related]
36. IAP antagonists: promising candidates for cancer therapy.
Mannhold R; Fulda S; Carosati E
Drug Discov Today; 2010 Mar; 15(5-6):210-9. PubMed ID: 20096368
[TBL] [Abstract][Full Text] [Related]
37. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
Eriksson A; Höglund M; Lindhagen E; Aleskog A; Hassan SB; Ekholm C; Fhölenhag K; Jensen AJ; Löthgren A; Scobie M; Larsson R; Parrow V
Biochem Pharmacol; 2010 Nov; 80(10):1507-16. PubMed ID: 20705060
[TBL] [Abstract][Full Text] [Related]
38. Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer.
Bosserman L; Rogers K; Willis C; Davidson D; Whitworth P; Karimi M; Upadhyaya G; Rutledge J; Hallquist A; Perree M; Presant CA
PLoS One; 2015; 10(5):e0122609. PubMed ID: 26024531
[TBL] [Abstract][Full Text] [Related]
39. The AutoDiSC: development and validation of a novel chemotherapy sensitivity and resistance assay.
Schinköthe T; Thiruchittampalam D; Schmidt A; Bomholt N; Staib P
Anticancer Res; 2013 Jun; 33(6):2491-8. PubMed ID: 23749900
[TBL] [Abstract][Full Text] [Related]
40. Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response.
Salom E; Penalver M; Homesley H; Burrell M; Garrett A; Presant CA; Rutledge J; Chernick M; Hallquist A; Perree M
J Transl Med; 2012 Aug; 10():162. PubMed ID: 22873358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
